Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids

This randomized study compared the efficacy and safety of lebrikizumab, montelukast, and placebo in 310 adult patients with mild-to-moderate asthma receiving a daily SABA. The primary endpoint was the absolute change in pre-bronchodilator FEV1; secondary endpoints included change in pre-bronchodilator PEF, time to treatment failure, change in SABA use, and change in asthma-specific health-related QoL (AQLQ overall score). As part of the study, patients used the Vitalograph In2itive e-Diary to record daily PEF measurements, montelukast compliance, daytime asthma symptoms, night-time awakenings, and daily SABA use.